Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension study of Lu AF11167 in patients with schizophrenia
2018-002708-15Phase 2Terminated
- Sponsor
- Lundbeck
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lu AF11167 in schizophrenia, sponsored by Lundbeck. Primary endpoint: Treatment-Emergent Adverse Events. Started Nov 2018; status: terminated.
02
Drugs
Lu AF11167
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-002708-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002708-15.